Commercial Insight: CNS Market Overview - Commercial dynamics and outlook of the neurology, pain and psychiatry market sectors

CHAPTER 1 EXECUTIVE SUMMARY 3
Scope of the analysis 3
Datamonitor insight into the CNS market 4
Related reports 5

CHAPTER 2 MARKET DEFINITION 9
Introduction 9
CNS sector sizing 9
Neurology and Psychiatry sector sizing methodologies 10
Pain 10
Geographic coverage 11

CHAPTER 3 BACKGROUND AND OVERVIEW 13
CNS market performance 15
Market comparison using the main CNS ATC1 class 15
ATC N class is the largest in terms of both sales value and sales volume 15
CNS market performance by sector 19
The CNS market totaled $95.48 billion in 2007 20
CNS market performance by region 25
High price points means US market dominates 7MM CNS market value 25
5EU sees greatest value growth over past 4 years 26
CNS disease sector comparison 27
Commercial viability of CNS sectors in 2015 28
Market dynamics of key CNS indications through to 2015 30
Growth to arise from all three key pain disease markets 30
Historical sector dynamics 31
Top-line sector comparisons 31
Brand dominance 33
Company dominance 34
Generic dominance 35
CNS product analysis 38
Leading brand analysis 38
Psychiatric brands take up 6 of the top 10 CNS brand positions 38
Case study analysis 1: versatile drug classes excel in the CNS market 40
N3A - Anticonvulsants 42
N5A - Antipsychotics 44
N6A - Antidepressants 46
Case study analysis 2: promotional spend in the CNS market 49
Promotional spend by region 49
Promotional spend by ATC4 class 50
Promotional spend by brand 52
Leading company involvement in the CNS market 54
Sales performance of the top 10 CNS companies of 2007 54
J&J consolidates its market leading position as its nearest rivals experience a decline in their CNS portfolios 54
Sector presence 56
Market leading company assessment 59
J&J -CNS franchise faces a challenging future following key patent expiries 59
Pfizer - Lyrica lays the groundwork for a new generation of CNS offerings 61
GSK - protecting its neurology portfolio remains the immediate focus 63
Forecast performance of other key CNS companies through to 2012 64
Tactical acquisitions to provide greater CNS market presence for UCB and Schering Plough 65

CHAPTER 4 NEUROLOGY 68
Market dynamics 69
Neurology market size and structure 69
US and EU are key neurology growth regions 69
Key indication market dynamics 70
Commercial viability of key neurological indications in 2015 71
Market dynamics and prevalence through to 2015 73
Historical sales dynamics of key neurological indications over the period 2004-07 75
Company analysis 81
Neurological drugs definition 81
Top five neurological drug companies' comparative marketed and pipeline portfolio potential 82
Historical performance and top-line dynamics of the leading neurological drug companies in 2007 84
Analysis of the top five neurological drug companies of 2007 87
Star performers within the neurological drug market - Emergence of UCB, Forest and Sepracor 98
Brand analysis 100
Anticonvulsants dominate the top 10 selling neurological drug brands 100
Key disease-specific insight 103
Alzheimer's disease 103
Key market insights 103
Market forecast summary 104
Disease definition 105
Epidemiology 106
Current market dynamics 107
Issues affecting the global Alzheimer's disease market 109
Key product launches and patent expiries through to 2016 113
Epilepsy 115
Key market insights 115
Market forecast summary 116
Disease definition 116
Epidemiology 118
Current market dynamics 120
Key companies and leading brands in the epilepsy market 123
Issues affecting the global epilepsy market 127
Key product launches and patent expiries through to 2016 131
Insomnia 133
Key market insights 133
Market forecast summary 134
Disease definition 135
Epidemiology 136
Current market dynamics 137
Key companies and leading brands in the Insomnia market 138
Issues affecting the global insomnia market 141
Key product launches and patent expiries through to 2016 143
Migraine 146
Key market insights 146
Disease definition 148
Epidemiology 149
Current market dynamics 151
Key companies and leading brands in the migraine market 154
Issues affecting the global migraine market 157
Key product launches and patent expiries through to 2016 163
Multiple Sclerosis 166
Key market insights 166
Market forecast summary 168
Disease definition 168
Epidemiology 169
Current market dynamics 170
Key companies and leading brands in the MS market 173
Environmental issues affecting the seven major MS markets 174
Key product launches and patent expiries through to 2016 178
Parkinson's disease 181
Key market insights 181
Market forecast summary 183
Disease definition 183
Epidemiology 184
Current market dynamics 186
Unmet needs in Parkinson's disease 187
Key product launches and patent expiries through to 2016 189
Other orphan neurological disorders 191
Amyotrophic lateral sclerosis (ALS/Motor neuron disease) 191
Huntington's disease 195

CHAPTER 5 PAIN 200
Market dynamics 202
Pain market size and structure 202
5EU is the key historical pain sector growth market 202
Key indication market dynamics 203
Commercial viability of key pain indications in 2015 204
Market dynamics and prevalence through to 2015 206
Historical sales dynamics of the three key pain indications over the period 2003-06 208
Company analysis 211
Pain drugs definition 211
Top five pain drug companies' comparative marketed and pipeline portfolio potential 212
Historical performance and top-line dynamics of the leading pain drug companies of 2007 214
Analysis of the top five pain drug companies of 2007 217
Star performer in the pain drug market 229
Major sector loser in the pain drug market 229
Brand analysis 230
Generic nature of pain sector sees leading brands being less dominant over market 230
Key non-traditional analgesics used in pain 231
Anticonvulsants for pain - Pregabalin and gabapentin gain significant revenues from neuropathic pain 232
Antidepressants for pain - Neuropathic pain an important revenue generator for Lilly's Cymbalta 233
Key disease-specific insight 234
Breakthrough pain 234
Key market insights 234
Market forecast summary 235
Disease definition 235
Epidemiology 236
Unmet needs in breakthrough pain 237
Fibromyalgia 237
Key market insights 237
Market forecast summary 238
Disease definition 239
Epidemiology 239
Current treatment approaches for fibromyalgia 240
Unmet needs in fibromyalgia 241
Neuropathic pain 242
Key market insights 242
Market forecast summary 243
Disease definition 243
Epidemiology 244
Current market dynamics 248
Current treatment approaches for neuropathic pain 249
Unmet needs in neuropathic pain 252
Traditional analgesic class dynamics 252
Opioids 252
Key market insights 253
Market forecast summary 253
Current market dynamics 254
Key product launches and patent expiries through to 2016 255
NSAIDs 258
Current market dynamics 258
Key brands in the NSAID market 262

CHAPTER 6 PSYCHIATRY 264
Market dynamics 266
Psychiatry market size and structure 266
US psychiatry sales dwarf that from the 5EU and Japan 266
Key indication market dynamics 267
Commercial viability of key psychiatric indications in 2015 268
Market dynamics and prevalence through to 2015 270
Historical sales dynamics of key psychiatric indications over the period 2003-06 273
Company analysis 276
Psychiatric drugs definition 276
Top five psychiatric drug companies' comparative marketed and pipeline portfolio potential 277
Historical performance and top-line dynamics of the leading psychiatric drug companies of 2008 279
Analysis of the top five psychiatric drug companies of 2007 282
Star performers within the psychiatric drug market - Teva and Reckitt Benckiser 297
Major psychiatric drug sector losers - Pfizer and GSK suffer after key antidepressants go generic 299
Brand analysis 301
Atypical antipsychotics and antidepressants fill nine of the top 10 places 301
Key non-traditional psychiatric drugs used in psychiatry 302
Anticonvulsants are regularly used to treat bipolar maintenance 303
Key disease-specific insight 304
Anxiety 304
Key market insights 304
Market forecast summary 304
Disease definition 305
Epidemiology 307
Current market dynamics 308
Unmet needs in Anxiety 309
ADHD 310
Key market insights 310
Market forecast summary 312
Disease definition 312
Epidemiology 313
Current market dynamics 316
Issues affecting the global ADHD market 318
Key product launches and patent expiries through to 2017 325
Bipolar disorder 328
Key market insights 328
Market forecast summary 329
Disease definition 330
Epidemiology 335
Current market dynamics 335
Unmet needs in bipolar disorder 338
Depression (Manic depressive disorder) 339
Key market insights 339
Market forecast summary 340
Disease definition 341
Epidemiology 342
Current market dynamics 343
Timeline of key events in the depression disease market 345
Issues affecting the global depression market 347
Key product launches and patent expiries through to 2016 351
Nicotine dependence 354
Key market insights 354
Market forecast summary 355
Disease definition 355
Epidemiology 357
Current market dynamics 358
Unmet needs in nicotine dependence 361
Schizophrenia 362
Key market insights 362
Market forecast summary 362
Disease definition 363
Epidemiology 364
Current market dynamics 364
Unmet needs in schizophrenia 365

BIBLIOGRAPHY 367
Literature 367
Websites 381
Datamonitor sources 389

APPENDIX A 392
International Classification of Diseases 392
Disease of the nervous system (neurology) 392
Mental and behavioral disorders (Psychiatry) 392
Estimated 2007 sales revenue 393
Top five sector drug companies' comparative marketed and pipeline portfolio potential methodology 393
Marketed potential 393
Pipeline potential 394
ATC classes included in 'others' to define the migraine market 395
ICD-10 codes used to define neuropathic pain market 396

APPENDIX B 398
Report methodology 398